Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPLE-LIPID-OUT
2026-525917-29-00Phase 4Authorised
- Sponsor
- Medical University of Graz
- Start
- Jul 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of rosuvastatin, ezetimibe and bempedoic acid in hypercholesterolemia, atherosclerotic disease, coronary arteriosclerosis and 1 more (2 arms), sponsored by Medical University of Graz. Primary endpoint: Achievement of LDL-C target at 12 weeks. Planned start Jul 2026; status: authorised.
02
Drugs
rosuvastatinezetimibebempedoic acid
03
Conditions
hypercholesterolemiaatherosclerotic diseasecoronary arteriosclerosisarteriosclerosis obliterans
Beyond the preview
Go deeper on 2026-525917-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525917-29-00.